Global Vaccine Market Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2024

The global vaccine market is expected to reach over USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. The presence of numerous molecules in the pipeline is anticipated to meet the demand for efficient vaccines. These include vaccines for chest infection, tuberculosis, malaria, and dengue. Most of the key players are actively leveraging on their vaccine development technologies to launch novel preventative solutions with an objective to increase their market share. For instance, Pfizer, Inc. is involved in the development of vaccines to prevent severe infections caused by Meningococcal B, Clostridium difficile, and Staphylococcus aureus.

Browse the report: http://www.orbisresearch.com/reports/index/vaccine-market-analysis-by-type-live-attenuated-vaccines-inactivated-vaccines-subunit-vaccines-toxoid-vaccines-conjugate-vaccines-dna-vaccines-by-application-infectious-diseases-cancer-autism-allergy-and-segment-forecasts-to-2024

Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.

For instance, the ‘Immunize Australia Program’ sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases. Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/106381

Further key findings from the study suggest:

The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines. In December 2015, Sanofi Pasteur, Inc. launched a new trivalent, inactivated polio vaccine in India.

The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area. Other advantages associated are ease of production, long lasting immunogenicity, and no risk of reversion.

The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.

North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region

Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India. Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.

Leading players in this industry, among others are, Merck & Co., Inc., Emergent BioSolutions, Inc., Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., Novartis AG, CSL Ltd., and GlaxoSmithKline Plc. Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.

In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its “Lipid Particle Vaccine” formulation technology to better the stability of the Sanofi vaccines.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

This release was published on openPR.